Emmaus Life Sciences, Inc. (EMMA)

OTCMKTS · Delayed Price · Currency is USD

0.0145

+0.0005 (3.57%)

At close: Mar 3, 2026

-17.14% (1Y)

Market Cap	1.02M
Revenue (ttm)	11.89M
Net Income (ttm)	-7.29M
Shares Out	70.19M
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,999
Average Volume	54,280
Open	0.0145
Previous Close	0.0140
Day's Range	0.0145 - 0.0145
52-Week Range	0.0080 - 0.0310
Beta	10.40
RSI	58.19
Earnings Date	Apr 7, 2026

About Emmaus Life Sciences

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Its pipeline products include ELS004, a pharmaceutical grade L-glutamine that is in Phase 1 clinical trial to treat diverticulosis. The com... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 35

Stock Exchange OTCMKTS

Ticker Symbol EMMA

Full Company Profile

Financial Performance

In 2024, Emmaus Life Sciences's revenue was $16.65 million, a decrease of -43.73% compared to the previous year's $29.60 million. Losses were -$6.45 million, 72.9% more than in 2023.

Financial Statements

News

There is no news available yet.